

# VU Research Portal

## Cerebrospinal fluid biomarkers in dementia with Lewy bodies

van Steenoven, I.

2020

### **document version**

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

### **citation for published version (APA)**

van Steenoven, I. (2020). *Cerebrospinal fluid biomarkers in dementia with Lewy bodies: towards a biological diagnosis*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam].

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

### **E-mail address:**

[vuresearchportal.ub@vu.nl](mailto:vuresearchportal.ub@vu.nl)

# CHAPTER 3

## CSF AD biomarkers across the spectrum of Lewy body diseases: Results from a large multicenter cohort

**Inger van Steenoven**, Dag Aarsland, Daniel Weintraub, Elisabet Londos, Frédéric Blanc, Wiesje M. van der Flier, Charlotte E. Teunissen, Brit Mollenhauer, Tormod Fladby, Milica G. Kramberger, Laura Bonanni, Afina W. Lemstra, on behalf of the European DLB consortium.

Journal of Alzheimer's disease, 2016

## ABSTRACT

**Background.** Concomitant Alzheimer disease (AD) pathology is observed in Lewy body diseases (LBD), but the clinical impact is unknown. Only a few biomarker studies in LBD exist and have included small cohorts from single centers.

**Objective.** We aimed to evaluate the prevalence of abnormal cerebrospinal fluid (CSF) AD biomarkers across the spectrum of LBD in a large multicenter cohort and to assess whether an AD biomarker profile was associated with demographic and clinical differences in dementia with Lewy bodies (DLB).

**Methods.** We included 375 DLB patients, 164 Parkinson's disease (PD) patients without dementia, and 55 PD patients with dementia (PDD) from 10 centers. CSF amyloid- $\beta$  1-42 (A $\beta$ 42), total Tau protein (t-tau), and phosphorylated Tau at threonine 181 (p-tau) values were dichotomized as abnormal or normal according to locally available cut-off values. A CSF AD profile was defined as abnormal A $\beta$ 42 combined with abnormal t-tau and/or p-tau.

**Results.** A substantial proportion of DLB patients had abnormal values for CSF A $\beta$ 42, t-tau and p-tau, while abnormal values were uncommon in PD without dementia. Patients with PDD had values in between. A CSF AD profile was observed in 25% of DLB patients, compared with only 9% of PDD and 3% of PD without dementia. Within DLB, patients with a CSF AD profile were older, more often female, performed worse on the Mini-Mental State Examination, and had shorter disease duration compared with patients with normal CSF.

**Conclusion.** A CSF AD profile is more common in DLB compared with PDD and PD, and is associated with more severe cognitive impairment in DLB.

## INTRODUCTION

Dementia with Lewy bodies (DLB) is the second most common neurodegenerative disease in the elderly after Alzheimer's disease (AD), accounting for 10-15% of the dementia cases at autopsy and 15-20% of dementia cases seen in dementia cohorts.<sup>1</sup> Recognizing DLB remains challenging due to the highly variable presentation of clinical symptoms, which include cognitive fluctuations, visual hallucinations, parkinsonism, sleep disorders and autonomic dysfunction,<sup>2</sup> and the fact there is considerable clinical and pathological overlap with both AD and Parkinson's disease (PD) and PD with dementia (PDD).

Pathologically, DLB is characterized by Lewy bodies and Lewy neurites composed of  $\alpha$ -synuclein aggregates in the brain, which are also the pathological hallmarks for PD and PDD<sup>3</sup>. In addition, a frequent finding in DLB is a varying degree of concomitant AD pathology (i.e., amyloid- $\beta$  plaques and neurofibrillary tangles (NFT)).<sup>2,4</sup> The role of AD pathology in the pathogenesis of DLB and its clinical impact remains unclear. Autopsy studies have suggested that DLB patients with concomitant AD pathology exhibit a more aggressive disease course and more pronounced cognitive dysfunction compared with pathologically pure AD or DLB patients.<sup>5-7</sup>

CSF biomarker analysis provides a means to evaluate ante mortem the underlying neuropathology in neurodegenerative diseases. The relevance of CSF biomarkers, amyloid- $\beta$  1-42 (A $\beta$ 42), total Tau protein (t-tau), and tau phosphorylated at threonine 181 (p-tau) for the diagnosis of AD is clearly established,<sup>8</sup> and these markers have been included in the proposed research criteria for the clinical diagnosis of AD.<sup>9</sup> Recently, evidence was provided that ante mortem CSF A $\beta$ 42 is correlated with pathologically proven concomitant AD pathology in DLB.<sup>10</sup> On the other hand, the accuracy of CSF biomarkers for the differential diagnosis of synucleinopathies is less well demonstrated. A number of studies have evaluated the potential value of CSF  $\alpha$ -synuclein as a diagnostic marker for Lewy body diseases, however, large variations in the absolute levels have been reported and the results were conflicting (see <sup>11</sup> for review).

To date, there are no specific CSF biomarkers for DLB, despite decades of research. This is partly related to the heterogeneity of DLB, the considerable overlap with AD and PD and the lack of a reliable biomarker for  $\alpha$ -synuclein deposition in the brain. A few AD CSF biomarker studies in DLB have reported reduced levels of A $\beta$ 42 compared with non-demented controls (see <sup>12</sup> for review). Similarly, reduced CSF A $\beta$ 42 levels predict cognitive decline in patients with PD.<sup>13,14</sup> Most CSF biomarker studies have included

small cohorts from single centers, and few studies across the full spectrum of Lewy body diseases (LBD: DLB, PDD and PD) have been performed.<sup>15, 16</sup> Therefore, the aim of the current study was to describe the prevalence of abnormal AD CSF biomarkers across the spectrum of LBD in a large multicenter cohort. In addition, we assessed whether a CSF AD biomarker profile was associated with demographic and clinical differences in DLB.

## METHODS

### Study population

From a European multicenter DLB study we included 594 patients with a clinical diagnosis of probable DLB, PDD or PD with available CSF biomarker data from 10 participating centers (academic memory clinics and movement disorder clinics) in eight countries. Detailed demographic data on DLB, PDD and PD patients from different centers are presented in Supplementary Table 1.

### Diagnostic and clinical procedures

The diagnosis of probable DLB was made according to the consensus diagnostic criteria,<sup>2</sup> the diagnosis of PD was made according to the UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria for PD,<sup>17</sup> and the diagnosis of PDD was made according to the diagnostic criteria by the MDS task force for dementia associated with PD.<sup>18</sup> In 92 DLB patients a [123I]FP-CIT SPECT scan was performed (25%) and of those 85 DLB patients had an abnormal [123I]FP-CIT SPECT scan (92%) to support the clinical diagnosis. For all centers, the assessment procedures included a detailed history, and physical, neurological, and neuropsychological examinations. Disease duration was defined as time between onset of first symptom and lumbar puncture. Global cognition was assessed with the Mini-Mental State Examination (MMSE) at most centers. For a subset of patients from two centers (Karolinska Institute, Stockholm and University of Pennsylvania, Philadelphia) the Montreal Cognitive Assessment (MoCA) was used. To be able to compare cognitive data the MoCA score for these 60 patients was converted to an equivalent MMSE score using a published formula.<sup>19</sup>

### Ethics

Local ethics committees at the individual centers approved the study. The patients gave their written consent to use the unidentified results of their clinical and biomaterial for research purposes.

## CSF procedures

The procedures to obtain and store CSF at the different centers are summarized in Supplementary Table 2. In all centers, CSF (1) was obtained by lumbar puncture in the L3-4 or L4-5 interspace; (2) collected in polypropylene tubes and centrifuged for 10 minutes at 4°C; and (3) stored in aliquots of 0.5 mL at -80°C or -70°C until further analysis.<sup>20</sup>

Three different assays were used to analyze the concentrations of CSF A $\beta$ 42, t-tau and p-tau in the samples: (1) Sandwich enzyme-linked immunosorbent assays [ELISA] INNOTEST®, formerly Innogenetics N.V., Ghent, Belgium, now Fujirebio (8 centers); (2) Luminex xMap technology using the Inno-Bia AlzBio3 kit, formerly Innogenetics, now Fujirebio (1 center); and (3) ELISA kit from Biosource Europe S.A (1 center). CSF biomarkers were dichotomized according to locally available cut-off values. An AD CSF profile was defined as abnormal (low) A $\beta$ 42 combined with abnormal (high) t-tau and/or p-tau.<sup>21,22</sup> Based on this profile, DLB, PDD and PD patients were categorized in an AD CSF profile positive group (AD+) and an AD CSF profile negative group (AD-).

## Statistical analysis

All statistical analyses were performed using IBM SPSS software for Mac, version 22.0. Differences between groups were assessed with ANOVA followed by Bonferroni post-hoc tests for continuous variables, or with Pearson Chi-Square tests for categorical variables, where appropriate. Multivariate logistic regression analysis was used to correct for age and gender in the between diagnostic group analyses. Differences between DLB AD+ and DLB AD- were determined with center adjusted (entered as dummies) ANOVA's for continuous variables or with logistic regression analyses for categorical variables. A  $p < 0.05$  was considered significant.

## RESULTS

### Patient characteristics

We included 594 patients of whom 375 were diagnosed with probable DLB, 55 were diagnosed with PDD and 164 were diagnosed with PD. Patient characteristics according to diagnosis are shown in Table 1. There were no differences in age, gender, education, MMSE score and duration of dementia diagnosis between DLB and PDD patients. PD patients were younger ( $p < 0.001$ ), and had higher level of education ( $p < 0.001$ ) and MMSE score ( $p < 0.001$ ) compared with DLB and PDD patients.

**Table 1** | Patient characteristics by diagnosis

	<b>DLB</b>	<b>PDD</b>	<b>PD</b>
<b>N</b>	375	55	164
<b>Age</b>	71.1 ± 8.4 <sup>a</sup>	71.1 ± 8.2 <sup>a</sup>	65.7 ± 7.2
<b>Sex</b> (% Male)	248 (66.5%)	41 (74.5%)	117 (71.3%)
<b>Education</b> (years)*	10.8 ± 3.7 <sup>a</sup>	11.8 ± 3.9 <sup>a</sup>	15.0 ± 3.2
<b>MMSE score</b> †	22.0 ± 5.4 <sup>a</sup>	22.6 ± 4.2 <sup>a</sup>	28.4 ± 1.7
<b>Disease Duration</b> (years)§	3.4 ± 2.9 <sup>a,c</sup>	8.3 ± 5.8 <sup>b</sup>	5.8 ± 4.7
<b>Duration of dementia diagnosis</b> (years)	3.4 ± 2.9	2.8 ± 2.4	n/a

Data are expressed as Mean ± SD for continuous variables, and as n (%) for categorical variables. Differences between groups were assessed with ANOVA followed by Bonferroni post-hoc test for continuous variables or with Pearson Chi-Square test for categorical variables. Abbreviations: DLB, dementia with Lewy bodies; MMSE, Mini-Mental State Examination; PD, Parkinson's disease; PDD, Parkinson's disease dementia \* DLB: n=258; PDD: n=49; PD: n=150, † DLB: n=365; PDD: n=53; PD: n=158, § DLB: n=352; PDD: n=41; PD: n=164. <sup>a</sup> $p < 0.001$  compared with PD, <sup>b</sup> $p < 0.05$  compared with PD, <sup>c</sup> $p < 0.001$  compared with PDD.

### CSF biomarkers by diagnosis

The percentages of patients with abnormal AD CSF biomarkers are shown in Table 2 and Figure 1. A large proportion of DLB patients had abnormal values of A $\beta$ 42 (49%), t-tau (28%) and p-tau (32%), and proportions were far lower in PD (A $\beta$ 42: 12%; t-tau: 4%, p-tau: 7%, all  $p < 0.001$ ). The prevalence of abnormal AD biomarkers in PDD was in between (A $\beta$ 42: 42%, PDD vs. DLB  $p = 0.31$ , PDD vs. PD  $p < 0.001$ ; t-tau: 17%, PDD vs. DLB  $p = 0.11$ , PDD vs. PD  $p < 0.05$ ; p-tau: 6%, PDD vs. DLB  $p < 0.05$ , PDD vs. PD  $p = 0.81$ ). When adjusted for age and gender using logistic regression, results remained essentially unchanged, with the exception of the difference between PDD and PD for t-tau, which lost significance.

A CSF profile compatible with AD (AD+) was observed in almost 25% of DLB patients, compared with only 9% of the PDD patients ( $p < 0.05$ ) and 3% of the PD patients ( $p < 0.001$ ) (Table 2 and Figure 1). When adjusted for age and gender using logistic regression, results remained essentially unchanged.


To further explore the validity of the findings we analyzed the percentages of abnormal AD CSF biomarkers and a CSF AD profile in only those 85 DLB patients with decreased dopamine transporter binding on a [123I]FP-CIT SPECT scan. The percentages were similar to those in the full data set.

**Table 2 |** AD CSF biomarkers by diagnosis

	<b>DLB</b> (n=375)	<b>PDD</b> (n=55)	<b>PD</b> (n=164)	<b>Chi square</b> <b>DLB vs PDD</b>	<b>Chi square</b> <b>DLB vs PD</b>	<b>Chi square</b> <b>PDD vs PD</b>	<b>*p-adjusted</b> <b>DLB vs PDD</b>	<b>*p-adjusted</b> <b>DLB vs PD</b>	<b>*p-adjusted</b> <b>PDD vs PD</b>
<b>Aβ42</b>									
Normal	190 (50.8%)	32 (58.2%)	145 (88.4%)	<i>p</i> =0.306	<i>p</i> <0.001	<i>p</i> <0.001	<i>p</i> =0.378	<i>p</i> <0.001	<i>p</i> <0.001
Abnormal	184 (49.2%)	23 (41.8%)	19 (11.6%)						
<b>t-tau</b>									
Normal	273 (73.2%)	45 (83.3%)	156 (95.7%)	<i>p</i> =0.110	<i>p</i> <0.001	<i>p</i> =0.003	<i>p</i> =0.171	<i>p</i> <0.001	<i>p</i> =0.059
Abnormal	100 (26.8%)	9 (16.7%)	7 (4.3%)						
<b>p-tau</b>									
Normal	239 (69.7%)	49 (94.2%)	153 (93.3%)	<i>p</i> <0.001	<i>p</i> <0.001	<i>p</i> =0.811	<i>p</i> =0.001	<i>p</i> <0.001	<i>p</i> =0.567
Abnormal	104 (30.3%)	3 (5.8%)	11 (6.7%)						
<b>CSF profile</b>									
AD-	292 (77.9%)	50 (90.9%)	159 (97.0%)	<i>p</i> =0.025	<i>p</i> <0.001	<i>p</i> =0.063	<i>p</i> =0.050	<i>p</i> <0.001	<i>p</i> =0.371
AD+	83 (22.1%)	5 (9.1%)	5 (3.0%)						

Data are expressed as n (%) for categorical variables. Differences between groups were assessed with Pearson Chi-Square test for categorical variables. \*Multivariate logistic regression analysis was used to correct for age and gender. Abbreviations: DLB, dementia with Lewy bodies; PD, Parkinson's disease; PDD, Parkinson's disease dementia; Aβ42, amyloid-β 1-42; p-tau, Tau phosphorylated at threonine 181; t-tau, total Tau protein.



**Figure 1 |** Percentage of patients with abnormal CSF biomarkers by diagnosis

Differences between groups were assessed with Pearson Chi-Square tests. Aβ42, amyloid-β 1-42; DLB, dementia with Lewy bodies; PD, Parkinson's disease; PDD, Parkinson's disease dementia; t-tau, total Tau protein; p-tau, Tau phosphorylated at threonine 181. \* $p < 0.05$ , \*\* $p < 0.001$ .

### AD+ CSF profile versus AD- CSF profile in DLB

To investigate whether an AD biomarker profile was associated with demographic and clinical differences in DLB, we compared DLB patients with an AD+ CSF profile (DLB AD+) to those without an AD CSF profile (DLB AD-). All analyses were adjusted for center. We found that the DLB AD+ group was older (74 vs. 70 years,  $p < 0.001$ ), more often female (49.4% vs. 29.1%,  $p < 0.001$ ), performed worse on the MMSE ( $20 \pm 6$  vs.  $23 \pm 5$ ,  $p < 0.05$ ) and had a shorter disease duration ( $2.8 \pm 1.6$  vs.  $3.5 \pm 3.1$  years,  $p < 0.05$ ) compared with DLB patients in the CSF AD- group (Table 3). The level of education did not differ between groups.

**Table 3** | Demographics of DLB AD+ CSF profile versus DLB AD- CSF profile

	DLB AD+	DLB AD-	<i>p</i>
N	83	292	
<b>Age</b>	73.8 ± 8.0	70.3 ± 8.3	<i>p</i> <0.001
<b>Sex</b> (% Male)	41 (50.6%)	207 (70.9%)	<i>p</i> <0.001
<b>Education</b> (years)*	10.2 ± 3.5	11.0 ± 3.8	<i>p</i> =0.281
<b>MMSE score</b> †	20.3 ± 6.0	22.6 ± 5.1	<i>p</i> <0.001
<b>Disease Duration</b> (years)§	2.8 ± 1.6	3.5 ± 3.1	<i>p</i> =0.025

Data are expressed as Mean ± SD and as n (%) for categorical variables. Differences between groups were assessed with center adjusted (entered as dummies) ANOVA's for continuous variables or with logistic regression analyses for categorical variables. \* DLB AD+: n=59; DLB AD-: n=199, † DLB AD+: n=79; DLB AD-: n=286, § DLB AD+: n=77; DLB AD-: n=275. Abbreviations: DLB, dementia with Lewy bodies; MMSE, Mini-Mental State Examination; PD, Parkinson's disease; PDD, Parkinson's disease dementia.

## DISCUSSION

In this large Lewy body diseases CSF multicenter cohort, we demonstrated that a substantial proportion of DLB patients have abnormal values for of the AD CSF biomarkers Aβ42, t-tau and p-tau, while abnormal AD CSF biomarkers were quite uncommon in PD. Patients with PDD had values in between. Moreover, our findings showed that around 25% of the DLB patients have a CSF profile compatible with AD, as defined by pathological Aβ42 combined with pathological t-tau or p-tau, and that a CSF AD profile was more common in DLB (almost 25%) than in PDD (9%) and PD (3%). Several studies have compared the levels of CSF Aβ42, t-tau and p-tau between DLB and PDD or between DLB and PD (see <sup>23</sup> for review), however only a few studies, with relatively small DLB sample sizes, have evaluated AD CSF biomarkers across the full spectrum of Lewy body diseases.<sup>15,16</sup> The aggregated data of these studies suggest that the CSF profiles of DLB, PDD and PD differ in the sense that DLB patients have a more AD-like CSF profile. Similar conclusions were also drawn based on amyloid imaging studies using Pittsburgh compound B (PIB) positron emission tomography (PET) which reported that cortical amyloid deposition is common in DLB, while it is lower in PDD and PD.<sup>24-27</sup> Together, these findings may reflect a difference in the underlying nature of DLB and PD(D), as it seems that in DLB AD pathology is quite common, while in PD(D) this is far less so.

In line with our findings, clinicopathological studies have also observed concomitant AD pathology in patients with DLB.<sup>28, 29</sup> The proportion of DLB patients with a CSF AD profile (25%) reported in the present study is smaller than reported in neuropathological studies (65-90%).<sup>7, 30-32</sup> Differences in the age of DLB patients may have been responsible for the discrepancy between the present CSF study (mean age 71 years) and neuropathological studies (age >80 years). Age is known to be the greatest risk factor for developing AD pathology. In our multicenter DLB cohort a CSF AD biomarker profile is more frequent in the older patients (71% in the age group >85 years versus 17% in the age group <65 years). In addition, AD pathology might develop over time in DLB. A recent CSF study in autopsy-verified DLB, in which a second lumbar puncture was performed in 4 cases, showed that in one DLB patient A $\beta$ 42 levels decreased over time below the pathological cut off value.<sup>10</sup> Longitudinal CSF or PiB-PET studies could contribute to the understanding of the progression of AD pathology during the course of DLB. A recent amyloid PET meta-analysis reported a prevalence of amyloid positivity in 51% of DLB patients and showed that amyloid positivity increased with age.<sup>33</sup> These results are in accordance with the present CSF study in which we have shown that 49% of the DLB patients had abnormal values of CSF A $\beta$ 42. A previous CSF study reported a CSF AD profile, defined by the Schoonenboom formula ( $A\beta_{42}/152 + 8.25 \times p\text{-tau} < 1$ ), in 47% of the DLB patients.<sup>34</sup> This is higher than the prevalence observed in the present CSF study, however the definition of a CSF AD profile we used in the present study is more conservative.

In the present study, we have shown that the proportion of patients with abnormal values of CSF A $\beta$ 42 was the lowest in PD (12%). This is in line with previous PiB-PET studies.<sup>27, 35</sup> According to a recent meta-analysis of PiB-PET studies in Lewy body diseases, the rate of amyloid positivity is 57%, 35%, 13% and 21% in DLB, PDD, PD and healthy controls, respectively.<sup>27</sup> Important to mention is that PD patients are younger than PDD patients in most studies. It is possible that AD pathology develops over time in a subset of PD patients, which is probably associated with APOE  $\epsilon$ 4 genotype.<sup>36, 37</sup> Noteworthy, it seems that amyloid positivity in PD patients is equally or even lower compared to healthy controls. Large studies of age-comparable healthy participants indicate an average of 20% amyloid- $\beta$  positivity.<sup>38</sup> This might suggest that PD is in some manner protective against amyloid- $\beta$  pathology. Further studies should investigate this hypothesis.

Further analysis of the DLB patients with a CSF AD biomarker profile in the present study revealed that those patients were older, more often female, had a shorter disease duration and had more cognitive impairment as assessed by the MMSE compared

with DLB patients who had an AD- (i.e., normal) CSF biomarker profile. These findings correspond with previous studies showing that a CSF AD biomarker profile in DLB was associated with older age and worse cognitive performance on the MMSE.<sup>34, 39</sup> Findings from clinicopathological studies suggest that multiple pathology (amyloid- $\beta$  plaques, neurofibrillary tangles and  $\alpha$ -synuclein inclusions) in DLB have synergistic action and contribute to cognitive decline.<sup>5, 6, 40</sup> In addition, studies in animal models showing that mice that develop both DLB and AD pathologies (3xTg-AD mice crossed with  $\alpha$ -syn<sub>A53T</sub> transgenic mice (M83)) exhibit accelerated cognitive decline assessed with the Barnes circular maze.<sup>41</sup> The aggregated evidence supports the hypothesis that AD pathology in DLB is associated with earlier and more rapid cognitive decline. However, more studies, preferably with a longitudinal design, are necessary to sustain this hypothesis.

One of the strengths of the present study was that we studied the presence of abnormal AD CSF biomarkers in patients across the spectrum of Lewy body diseases. Furthermore, this multicenter collaboration avoids several of the risks of biases associated with single-center studies by having included substantially more patients than previous CSF studies. However, there are a number of limitations that need to be considered in interpreting this study. First, we used retrospective data from different cohorts, which may have introduced bias due to differences in study designs. For example, we noticed a considerable variability in the prevalence of DLB patients with abnormal values of CSF A $\beta$ 42 across centers (Supplementary Table 1). The variation in prevalence between centers could be caused either by variations in pre-analytical sample handling and ELISA assays (Supplementary Table 2), by cohort characteristics or by diagnostic differences. However, careful comparison of the pre-analytical sample handling procedures did not reveal considerable differences between centers and all centers used the McKeith clinical diagnostic criteria for DLB. This study lacks autopsy confirmation of the diagnosis. Considering the low sensitivity of the current clinical diagnostic criteria for DLB, the clinical diagnosis may thus not be correct for all cases and the accuracy of the clinical diagnoses could differ between centers. However, the investigators involved in the present study have extensive clinical experience in diagnosing DLB and PD, and 23% of DLB patients had a [123I]FP-CIT SPECT scan to support the clinical diagnosis. Nevertheless, the differences between centers emphasize the importance of accurately following harmonization protocols and guidelines for pre-analytic sample handling, biochemical procedures as well as the clinical assessments of the patients. The recent established DLB consortium has developed guidelines and protocol recommendations for future prospective cohort studies in DLB, which have been published on the website of the EU Joint Programme – Neurodegenerative Disease (JPND) Research.<sup>42</sup>

In this study, we only evaluated the presence of AD CSF biomarkers. As aggregates of  $\alpha$ -synuclein protein are the main components of Lewy bodies, the pathologic hallmark of PD, PDD, and DLB, it will be interesting to evaluate  $\alpha$ -synuclein in the CSF of patients with these diseases. To date, however, no robust CSF test for  $\alpha$ -synuclein is clinically available. Future research is needed to evaluate whether  $\alpha$ -synuclein species could be reliable biomarkers for the diagnosis and early detection of LBD.

In conclusion, in this large multicenter CSF study we showed that (1) a substantial proportion of DLB patients had abnormal values for AD CSF biomarkers A $\beta$ 42, t-tau and p-tau, (2) approximately 25% of DLB patients have a CSF profile compatible with AD compared with only 9% of PDD patients and 3% of PD patients and (3) a CSF AD profile in DLB patients is associated with a more severe disease course. AD biomarkers in vivo mirror the neuropathological substrate of cognitive impairment across Lewy body diseases. Recognition of the presence of a CSF AD biomarker profile in DLB patients may advance patient guidance and individualization of treatment strategies. In addition, disease-modifying treatments directly targeting amyloid and tau aggregates, which are currently under development for AD, may have clinical value in DLB as well. CSF could be used to select DLB-patients for future trials and DLB patients with a CSF profile compatible with AD could be included in future trials of AD disease-modifying treatments. The recognition of considerable variability of the presence of AD biomarkers between DLB, PDD, and PD is important for the identification of molecular mechanisms involved in the Lewy body diseases. Future research is warranted to gain more insight into the molecular mechanisms underlying the pathophysiology and to further elucidate the contribution of concomitant AD pathology towards the clinical manifestation of Lewy body diseases.

### Acknowledgements

The authors express their thanks to all the members of the E-DLB consortium. Dag Aarsland, Stavanger University Hospital, Stavanger, Norway; Angelo Antonini, Center for Parkinson's disease and Movement Disorder Venice-Lido, Italy; Carla Abdelnour Ruiz, Fundació ACE, Spain; Clive Ballard, Kings College London, UK; Alexandra Bernadotte, RAMS, St Petersburg, Russia; Roberta Biundo, Center for Parkinson's disease and Movement Disorder Venice-Lido, Italy; Frédéric Blanc, University of Strasbourg, Strasbourg, France; Bradly Boeve, Mayo Clinic Rochester, USA; Laura Bonanni, Department of Neuroscience and Imaging, Università "G. D'Annunzio" Chieti - Pescara, Italy; Sevasti Bostantjopoulou, Aristotle University of Thessaloniki, Greece; Richard Dodel, University Hospital Marburg, Germany; Cristian Falup-Pecurariu, Transilvania University of Brasov, Romania; Tormod Fladby University of Oslo, Norway; Sara

Garcia-Pacek, Karolinska Institutet, Sweden; Josep Garre, University of Girona, Spain; Gert J. Geurtsen, AMC Amsterdam, The Netherlands; Oskar Hansson, Lund University, Sweden; Frank Jan de Jong, Erasmus MC Rotterdam, The Netherlands; Zoe Katsarou, Aristotle University of Thessaloniki, Greece; Milica G. Kramberger, Ljubljana University Medical Centre, Ljubljana, Slovenia; Afina W. Lemstra, VU University Medical Center, Amsterdam, The Netherlands; Elisabet Londos, Lund University, Malmö, Sweden; Ian McKeith, Newcastle University, UK; Brit Mollenhauer, Paracelsus-Elena-Klinik, Kassel, Germany; Flavio Nobili, University of Genoa, Italy; Maria Petrova, University Hospital "Alexandrovska", Bulgaria; Irena Rektorova, Masaryk University, Czech Republic; Arvid Rongve, Haugesund Hospital, Norway; Inger van Steenoven, VU University Medical Center, Amsterdam, The Netherlands; Elka Stefanova, University of Belgrade, Serbia; Per Svenningsson, Karolinska Institutet, Sweden; John Paul Taylor, Newcastle University, UK; Latchezar Traykov, University Hospital "Alexandrovska", Bulgaria; Zuzana Walker, University College London, UK; Daniel Weintraub, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA. Eric Westman, Karolinska Institutet, Sweden; Bengt Winblad, Karolinska Institutet, Sweden; and Henrik Zetterberg, University of Gothenburg, Sweden.

## REFERENCES

1. Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. *The Lancet*. 2015;386(10004):1683-97.
2. McKeith I, Dickson D, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. *Neurology*. 2005;65:1863-72.
3. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of  $\alpha$ -synuclein in neurological disorders. *The Lancet Neurology*. 2011;10(11):1015-25.
4. Cummings JL. Dementia with lewy bodies: molecular pathogenesis and implications for classification. *Journal of geriatric psychiatry and neurology*. 2004;17(3):112-9.
5. Howlett DR, Whitfield D, Johnson M, et al. Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias. *Brain Pathology*. 2014.
6. Kraybill ML, Larson EB, Tsuang D, et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. *Neurology*. 2005;64(12):2069-73.
7. Merdes A, Hansen L, Jeste D, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. *Neurology*. 2003;60(10):1586-90.
8. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. *Nature Reviews Neurology*. 2010;6(3):131-44.
9. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. *The Lancet Neurology*. 2007;6(8):734-46.
10. Brunnström H, Hansson O, Zetterberg H, Londos E, Englund E. Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies. *International journal of geriatric psychiatry*. 2013;28(7):738-44.
11. Simonsen AH, Kuiperij B, El-Agnaf OMA, et al. The utility of  $\alpha$ -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. *Biomarkers in medicine*. 2016;10(1):19-34.
12. Schade S, Mollenhauer B. Biomarkers in biological fluids for dementia with Lewy bodies. *Alzheimer's research & therapy*. 2014;6(5):72.
13. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid  $\{\beta\}$  1-42 predicts cognitive decline in Parkinson disease. *Neurology*. 2010 Sep 21;75(12):1055-61.
14. Alves G, Lange J, Blennow K, et al. CSF A $\beta$ 42 predicts early-onset dementia in Parkinson disease. *Neurology*. 2014;82(20):1784-90.
15. Hall S, Öhrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. *Archives of neurology*. 2012;69(11):1445-52.
16. Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies. *Biological Psychiatry*. 2008;64(10):850-5.
17. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *Journal of Neurology, Neurosurgery & Psychiatry*. 1992;55(3):181-4.



18. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. *Movement Disorders*. 2007;22:1689-707.
19. Steenoven I, Aarsland D, Hurtig H, et al. Conversion between Mini-Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale-2 scores in Parkinson's disease. *Movement Disorders*. 2014.
20. Teunissen C, Petzold A, Bennett J, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. *Neurology*. 2009;73(22):1914-22.
21. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia*. 2011;7(3):263-9.
22. Duits FH, Teunissen CE, Bouwman FH, et al. The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean? *Alzheimer's & Dementia*. 2014;10(6):713-23.
23. Mollenhauer B, Parnetti L, Rektorova I, et al. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. *Journal of neurochemistry*. 2015.
24. Gomperts SN. Imaging the role of amyloid in PD dementia and dementia with Lewy bodies. *Current neurology and neuroscience reports*. 2014;14(8):1-9.
25. Gomperts SN, Marquie M, Locascio JJ, Bayer S, Johnson KA, Growdon J. PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies. *Neurodegenerative Diseases*. 2015:118-24.
26. Gomperts SN, Locascio JJ, Marquie M, et al. Brain amyloid and cognition in Lewy body diseases. *Movement Disorders*. 2012;27(8):965-73.
27. Donaghy P, Thomas AJ, O'Brien JT. Amyloid PET imaging in Lewy body disorders. *The American Journal of Geriatric Psychiatry*. 2015;23(1):23-37.
28. Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. *Acta neuropathologica*. 2011;122(2):187-204.
29. Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. *Acta neuropathologica*. 2008;115(4):427-36.
30. Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. *Acta neuropathologica*. 2001;102(4):355-63.
31. Dugger BN, Adler CH, Shill HA, et al. Concomitant pathologies among a spectrum of parkinsonian disorders. *Parkinsonism & related disorders*. 2014;20(5):525-9.
32. Schneider J, Arvanitakis Z, Yu L, Boyle P, Leurgans S, Bennett D. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. *Brain*. 2012;135(10):3005-14.
33. Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. *Jama*. 2015;313(19):1939-50.



34. Schoonenboom N, Reesink F, Verwey N, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. *Neurology*. 2012;78(1):47-54.
35. Foster ER, Campbell MC, Burack MA, et al. Amyloid imaging of Lewy body-associated disorders. *Movement Disorders*. 2010;25(15):2516-23.
36. Williams-Gray CH, Goris A, Saiki M, et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's Disease. *Journal of neurology*. 2009 Mar;256(3):493-8.
37. Mata IF, Leverenz JB, Weintraub D, et al. APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. *JAMA Neurol*. 2014 Nov;71(11):1405-12.
38. Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. *Jama*. 2015;313(19):1924-38.
39. Andersson M, Zetterberg H, Minthon L, Blennow K, Londos E. The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia. *International Journal of Geriatric Psychiatry*. 2011;26(1):100-5.
40. Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. *Neurology*. 2006;67(11):1931-4.
41. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic interactions between A $\beta$ , tau, and  $\alpha$ -synuclein: acceleration of neuropathology and cognitive decline. *The Journal of Neuroscience*. 2010;30(21):7281-9.
42. Aarsland D. Multi-centre cohort studies in Lewy-Body Dementia: Challenges in harmonizing different clinical and biomarker protocols. Retrieved from National Center for Education Statistics website: <http://www.neurodegenerationresearch.eu/wp-content/uploads/2015/10/JPND-Report-Aarsland.pdf>2015.

## SUPPLEMENTAL DATA

Supplementary Table 1 | Characteristics of the cohorts by diagnosis

	Amsterdam (n=99)	Chieti (n=8)	Kassel (n=67)	Ljubljana (n=30)	Malmö/Lund (n=113)	Oslo (n=38)
<b>Disease state (n)</b>	DLB (n=99)	DLB (n=8)	DLB (n=67)	DLB (n=7)	DLB (n=92)	PD (n=38)
<b>Age</b>	(n=99) 67.6 ± 8.3	(n=8) 84.0 ± 8.2	(n=66) 71.5 ± 6.0	(n=7) 75.4 ± 7.2	(n=92) 74.5 ± 6.2	(n=38) 65.3 ± 6.6
<b>Sex (% Male)</b>	83 (83.8%)	6 (75.0%)	43 (64.2%)	3 (42.9%)	54 (60.0%)	25 (65.8%)
<b>Education (years)</b>	(n=86) 10.7 ± 3.1	(n=7) 11.0 ± 4.9	n/a	(n=7) 10.1 ± 2.0	(n=73) 10.6 ± 3.4	(n=38) 12.9 ± 3.6
<b>MMSE score</b>	(n=95) 22.2 ± 4.6	(n=8) 19.4 ± 3.7	(n=64) 19.1 ± 6.8	(n=7) 22.4 ± 3.3	(n=90) 22.6 ± 5.1	(n=38) 28.4 ± 2.0
<b>Disease duration (years)</b>	(n=94) 3.0 ± 2.0	(n=8) 3.0 ± 3.0	(n=54) 2.1 ± 1.9	(n=7) 1.3 ± 0.5	(n=88) 3.2 ± 2.4	(n=37) 2.4 ± 1.2
<b>Aβ42</b>						
Abnormal values (%)	37 (37.4%)	5 (62.5%)	28 (42.4%)	4 (57.1%)	77 (83.7%)	1 (2.6%)
Normal values (%)	62 (62.6%)	3 (37.5%)	38 (57.6%)	3 (42.9%)	15 (16.3%)	37 (97.4%)
<b>t-tau</b>						
Abnormal values (%)	32 (32.3%)	1 (12.5%)	9 (13.4%)	1 (14.3%)	32 (35.2%)	3 (7.9%)
Normal values (%)	67 (67.7%)	7 (87.5%)	58 (86.6%)	6 (85.7%)	59 (64.8%)	35 (92.1%)
<b>p-tau</b>						
Abnormal values (%)	45 (45.5%)	0 (0%)	17 (36.2%)	1 (14.3%)	12 (15.0%)	2 (5.3%)
Normal values (%)	54 (54.5%)	8 (100%)	30 (63.8%)	6 (85.7%)	68 (85.0%)	36 (94.7%)
<b>AD+ CSF profile</b>						
Positive (%)	24 (24.2%)	1 (12.5%)	9 (13.4%)	1 (14.3%)	29 (31.5%)	0 (0%)
Negative (%)	75 (75.8%)	7 (87.5%)	58 (86.6%)	6 (85.7%)	63 (68.5%)	38 (100%)

**Supplementary Table 1 |** Characteristics of the cohorts by diagnosis (continued)

	Pennsylvania (n=114)		Stavanger (n=9)		Stockholm (n=45)		Strasbourg (n=71)	
<b>Disease state (n)</b>	PDD (n=11)	PD (n=103)	DLB (n=7)	PDD (n=2)	DLB (n=24)	PDD (n=21)	DLB (n=71)	
<b>Age</b>	(n=11) 76.2 ± 6.4	(n=103) 65.4 ± 7.6	(n=7) 71.9 ± 9.2	(n=2) 62.5 ± 10.6	(n=24) 72.8 ± 6.2	(n=21) 66.6 ± 7.9	(n=71) 68.6 ± 10.0	
<b>Gender (% Male)</b>	10 (90.9%)	79 (76.7%)	4 (57.1%)	1 (50.0%)	17 (70.8%)	15 (71.4%)	38 (53.5%)	
<b>Education (years)</b>	(n=11) 14.8 ± 3.0	(n=91) 16.3 ± 2.2	(n=7) 8.7 ± 1.8	(n=2) 11.5 ± 5.0	(n=22) 11.9 ± 4.0	(n=20) 12.2 ± 3.6	(n=56) 11.2 ± 4.8	
<b>MMSE score</b>	(n=11) 21.2 ± 4.3	(n=100) 28.4 ± 1.7	(n=7) 24.1 ± 2.1	(n=2) 26.5 ± 2.1	(n=24) 23.8 ± 4.1	(n=21) 23.5 ± 3.9	(n=70) 23.6 ± 5.3	
<b>Disease duration (years)</b>	(n=11) 11.6 ± 7.7	(n=103) 7.4 ± 5.2	(n=6) 4.0 ± 1.7	-	(n=24) 2.4 ± 2	(n=21) 8.0 ± 4.2	(n=71) 5.4 ± 4.4	
<b>Aβ42</b>								
Abnormal values (%)	7 (63.6%)	18 (17.5%)	7 (100.0%)	2 (100%)	6 (25%)	3 (14.3%)	20 (28.2%)	
Normal values (%)	4 (36.4%)	85 (82.5%)	0 (0.0%)	0 (0%)	18 (75%)	18 (85.7%)	51 (71.8%)	
<b>t-tau</b>								
Abnormal values (%)	2 (18.2%) <sup>§</sup>	3 (2.9%)	4 (57.1%)	0 (0%)	7 (29.2%)	1 (4.8%)	14 (20.0%)	
Normal values (%)	9 (81.8%)	99 (97.1%)	3 (42.9%)	2 (100%)	17 (70.8%)	20 (95.2%)	56 (80.0%)	
<b>p-tau</b>								
Abnormal values (%)	0 (0%)	9 (8.7%)	4 (57.1%)	0 (0%)	1 (4.2%)	1 (4.8%)	24 (33.8%)	
Normal values (%)	11 (100%)	94 (91.3%)	3 (42.9%)	2 (100%)	23 (95.8%)	20 (95.2%)	47 (66.2%)	
<b>AD+ CSF profile</b>								
Positive (%)	1 (9.1%)	5 (4.9%)	4 (57.1%)	0 (0%)	3 (12.5%)	0 (0%)	12 (16.9%)	
Negative (%)	10 (90.9%)	98 (95.1%)	3 (42.9%)	2 (100%)	21 (87.5%)	21 (100%)	59 (83.1%)	

Data are expressed as Mean ± SD for continuous variables, and as n (%) for categorical variables. Abbreviations: MMSE, Mini-Mental State Examination; Aβ42, amyloid-β 1-42; p-tau, tau phosphorylated at threonine 181.

**Supplementary Table 2** | Overview of CSF procedures

Center	Centrifuging	Storage	Analysis Essay	Cut off values [ng/L]
Oslo	Centrifuged at 2000g for 10 minutes at 4°C	Stored at -80°C	INNOTEST Double sandwich ELISAs	Aβ42: <600 t-tau: >450 p-tau: >80
Chieti	Centrifuged at 4000g for 10 minutes at 4°C	Aliquots of 0.5mL stored in polypropylene tubes at -80°C	INNOTEST Double sandwich ELISAs	Aβ42: <800 t-tau: >300 p-tau: >60
Stavanger	Centrifuged at 2000g for 10 minutes at 4°C	Stored in polypropylene tubes at -80°C	Aβ42: Biosource Europe S.A. t-tau: INNOTEST hTau p-tau: INNOTEST Phos-pho-Tau (181)	Aβ42: <482 t-tau: >320 p-tau: >52
Stockholm	Centrifuged at 2000g for 10 min at 4°C	Aliquots of 0.5mL of 1mL stored in polypropylene tubes at -80°C	INNOTEST Double sandwich ELISAs	Aβ42: <550 t-tau: >400 p-tau: >80
Ljubljana	Centrifuged at 4000g for 10 minutes at 2-4°C	Stored at -70°C	INNOTEST Double sandwich ELISAs	Aβ42: <550 t-tau: >400 p-tau: >80
Malmö/Lund	Centrifuged at 2000g for 10 minutes at 4°C	Stored at -80°C	INNOTEST Double sandwich ELISAs	Aβ42: <550 t-tau: >400 p-tau: >80
Kassel	Centrifuged at 3200 rpm for 10 minutes at 4°C	Stored at -80°C	INNOTEST Double sandwich ELISAs	Aβ42: <450 t-tau: >450 p-tau: >61
Pennsylvania	Not done	Aliquots of 0.5mL stored in polypropylene tubes at -80°C	INNO-BIA AlzBio3	Aβ42: <192 t-tau: >93 p-tau: >32
Strasbourg	Centrifuged at 1000g for 10 minutes at 4°C	Aliquots of 0.5mL stored in polypropylene tubes at -80°C	INNOTEST Double sandwich ELISAs	Aβ42: <500 t-tau: 50-70 years: >450 >70 years: >500 p-tau: >60
Amsterdam	Centrifuged at 1800g for 10 minutes at 4°C	Aliquots of 0.5mL stored in polypropylene tubes at -80°C	INNOTEST Double sandwich ELISAs	Aβ42: <550 t-tau: >375 p-tau: >52

Abbreviations: Aβ42, amyloid-β 1-42; DLB, dementia with Lewy bodies; ELISA, enzyme-linked immunosorbent assay; PD, Parkinson's disease; PDD, Parkinson's disease dementia; p-tau, Tau phosphorylated at threonine 181; t-tau, total Tau protein.



